Ex-Shire Team Builds New Euro-Specialty Group
Executive Summary
Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.
You may also be interested in...
Europe's New Spec Pharma Models
Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.
Europe's New Spec Pharma Models
Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.
Cephalon: Can Spec Pharma do R&D?
Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.